Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone

View through CrossRef
Abstract Aims To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science. Methods We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it. The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference. The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions. Main results and conclusions (1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E. Gley (1900), GL Zülzer (1908) and NC Paulescu (1920). (2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same. (3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic. (4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: "the credit for having produced the pancreatic hormone in a practical available form" (instead of “for the discovery of insulin”).
Title: The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone
Description:
Abstract Aims To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated.
A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science.
Methods We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it.
The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference.
The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions.
Main results and conclusions (1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E.
Gley (1900), GL Zülzer (1908) and NC Paulescu (1920).
(2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same.
(3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic.
(4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: "the credit for having produced the pancreatic hormone in a practical available form" (instead of “for the discovery of insulin”).

Related Results

EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Nuevas ideas para la paz y el Premio Internacional de la Paz Johan Galtung
Nuevas ideas para la paz y el Premio Internacional de la Paz Johan Galtung
Excepting the Nobel Peace Prize, most of the international peace prizes are little known; some are not even regularly awarded; and a number of these, including the Nobel Peace Priz...
The emergence of Applied Physiology within the discipline of Physiology
The emergence of Applied Physiology within the discipline of Physiology
Despite the availability and utilization of the physiology textbooks authored by Albrecht von Haller during the 18th century that heralded the modern age of physiology, not all phy...
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
1. A technique for indirectly labelling antibodies to polypeptide hormones, by combining them with radioactively labelled anti-(immunoglobulin G) is described. (a) 125I-labelled an...
Nobel prize laureates for chemistry in the period 2000-2021
Nobel prize laureates for chemistry in the period 2000-2021
The Nobel Prize in Chemistry has a long history since 1901. There were significant changes and discoveries in chemistry in the previous period, especially intensified in the period...
Research Progress of Diterpenoids with Potential Antidiabetic Activity
Research Progress of Diterpenoids with Potential Antidiabetic Activity
Introduction: Diabetes mellitus has become a global epidemic. Diterpenoids have complex and variable structures and are widely distributed in nature. They play a crucial role in di...
Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus
Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus
AbstractBackgroundThere is a lack of consensus on prescribing alternatives to initial metformin therapy and intensification therapy for type 2 diabetes mellitus (T2DM) management. ...

Back to Top